Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

This Time Around, Debate Much Different
Insurance companies, "the industry that gets credit for helping to kill the Clinton administration"s health care overhaul 15 years ago," are now "striking a conciliatory tone as it faces the most serious attempt to overhaul the system since that effort collapsed," CQ Politics reports. With low favorability ratings and Democrats in control of the federal government, "insurers know they aren"t in a good bargaining position" this time around. They have already offered concessions, including providing "insurance in the individual markets to everyone, without regard to who is sick," and not "charging people who are ill higher rates and cut health care costs." But they"ve also been ""careful to structure their offers in such a way that appears significant but does not overpromise." An individual mandate for all Americans and an end to health screening for applicants could offer "a win-win outcome, one that will benefit not just patients but potentially the profits of the industry as well." But "perhaps the biggest motivation for insurers to deal now is that they fear what might happen if they don"t" - the "creation of a government-run plan that would be more attractive to the public and siphon off customers" (Adams, 6/1).
generic viagra online
Variation Of Natural Compound Cures Malaria In Mice
Approximately 350 million to 500 million cases of malaria are diagnosed each year mostly in sub-Saharan Africa. While medications to prevent and treat malaria do exist, the demand for new treatments is on the rise, in part, because malaria parasites have developed a resistance to existing medications. Now, researchers at the Johns Hopkins University School of Medicine have discovered one way to stop malaria parasite growth, and this new finding could guide the development of new malaria treatments. Drugshop to buy zoloft online and other pills.
News of the day
California's Private Employer Health Premiums Increased 138% Last Decade; Healthy Families & Medi-Cal Premium Increases Substantially Lower
Private business in California saw health care premiums increase by 138
Diagnostics

AcelRx Announces Perfect Performance Of Handheld Component Of ARX-01 Sufentanil NanoTab PCA System In A Phase 2 Study

AcelRx Pharmaceuticals, Inc. announced positive results from its first Phase 2 clinical study evaluating the functionality of the handheld device component of its ARX-01 Sufentanil NanoTab(TM) PCA System for management of acute post-operative pain in patients requiring opioid analgesia during hospitalization. Patients reliably self-administered sufentanil NanoTabs repeatedly over the 12-hour study without any ARX-01 System failures or dosing errors of any kind. This multicenter, open-label study included 30 patients (median age 68; range 51-74) undergoing elective unilateral knee replacement surgery. Patients self-administered 15 mcg doses of ARX-01 Sufentanil NanoTabs sublingually as needed using the ARX-01 handheld, with a minimal re-dosing interval of 20 minutes. The primary endpoint was device functionality assessed as the proportion of patients who successfully completed the study without any type of System failure. There were no System failures or dosing errors of any kind throughout the study, which included over 375 dispensed NanoTabs. Additionally, preliminary analysis of efficacy results indicated a dropout rate due to inadequate analgesia of less than 10%, consistent with the superior efficacy reported for the 15 mcg dose in two earlier Phase 2 placebo-controlled studies. ARX-01 was well-tolerated, and there were no serious adverse events related to study drug. AcelRx Chief Engineering Officer, Anil Dasu, commented, "These results confirm the simple usability and consistent functionality of the handheld component of the ARX-01 Sufentanil NanoTab PCA System in the hands of post-surgical patients. Not only have the patients been pleased with the ease of use of the ARX-01 System, but the medical staff has also been highly satisfied with System"s ease and speed of set-up and reliability." In addition to this device functionality study, AcelRx has conducted two placebo-controlled Phase 2 studies of ARX-01 Sufentanil NanoTabs in patients undergoing elective unilateral knee replacement surgery and in patients undergoing major abdominal surgery. Both of those studies demonstrated highly significant efficacy results for the 15 mcg dose relative to placebo in reducing pain intensity over the 12-hour study periods. About Acute Post-Operative Pain Annually, approximately 8 million patients in the U.S. receive intravenous (IV) patient-controlled analgesia (PCA), typically utilizing morphine, for inpatient post-operative pain, with a similar number in the E.U. Despite its widespread use, the IV PCA architecture has several limitations. The IV line tethering the patient to the PCA pump discourages mobility, which is a critical factor in preventing post-operative complications and advancing recovery. Furthermore, the invasive nature of the IV delivery mode poses infection risk as well as predisposition to analgesic gaps due to infiltrated and dislodged IV catheters. Additionally, the complexity and programmability of IV PCA pumps introduce opportunities for medication errors, which in some instances may be fatal. About ARX-01 Sufentanil NanoTab PCA System ARX-01 is a novel drug/device combination product candidate designed for use in hospital settings to provide non-invasive patient-controlled analgesia and maximize patient satisfaction with post-operative pain management. The ARX-01 Sufentanil NanoTab PCA System avoids many of the limitations of IV PCA approaches by providing a non-invasive, pre-programmed, handheld PCA solution. The handheld component of ARX-01 allows for convenient patient selfadministration of sufentanil NanoTabs sublingually for oral transmucosal absorption. Sufentanil is a high therapeutic index opioid approved for IV and epidural administration. Although the analgesic efficacy of sufentanil has been well established, its use has been limited due to its short IV plasma half-time. In the NanoTab oral transmucosal dosage form, sufentanil demonstrates a therapeutically appropriate pharmacokinetic profile for post-operative PCA usage and has the potential for improved patient tolerability over IV PCA morphine. About AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary NanoTab dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of currently approved compounds. AcelRx Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009